Bulletin
Investor Alert

Annovis Bio Inc.

NYS: ANVS

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 27, 2023, 5:53 p.m.

/zigman2/quotes/216213707/composite

$

15.46

Change

+0.21 +1.38%

Volume

Volume 1,005

Quotes are delayed by 20 min

/zigman2/quotes/216213707/composite

Previous close

$ 13.70

$ 15.25

Change

+1.55 +11.31%

Day low

Day high

$13.70

$16.81

Open

52 week low

52 week high

$8.39

$23.91

Open

Company Description

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic...

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Valuation

Price to Book Ratio

3.20

Enterprise Value to EBITDA

-4.55

Efficiency

Liquidity

Current Ratio

30.54

Quick Ratio

30.54

Cash Ratio

30.33

Profitability

Return on Assets

-53.54

Return on Equity

-55.68

Return on Total Capital

-55.87

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Maria-Luisa Maccecchini 70 2008 President, Chief Executive Officer & Director
Dr. Cheng Fang - 2021 Vice President-Research
Ms. Eve M. Damiano - 2022 Senior Vice President-Regulatory Operations
Mr. Michael B. Hoffman 70 2014 Director

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/14/2022 Maria-Luisa Maccecchini
President and CEO; Director
32,959   Derivative/Non-derivative trans. at $0.14 per share. 4,614
01/04/2022 Michael B. Hoffman
Director
90   Derivative/Non-derivative trans. at $19.78 per share. 1,780
01/04/2022 Michael B. Hoffman
Director
6,658   Derivative/Non-derivative trans. at $19.78 per share. 131,695
01/04/2022 Michael B. Hoffman
Director
7,142   Derivative/Non-derivative trans. at $0.25 per share. 1,785
01/04/2022 Michael B. Hoffman
Director
30,000   Derivative/Non-derivative trans. at $4.39 per share. 131,700
12/20/2021 Maria-Luisa Maccecchini
President and CEO; Director
20,000   Gift at $0 per share. 0
10/12/2021 Mark White
Director
5,000   Acquisition at $27.4 per share. 137,000
10/11/2021 Maria-Luisa Maccecchini
President and CEO; Director
18,000   Acquisition at $27.61 per share. 496,980
10/11/2021 Claudine E. Bruck
Director
181   Acquisition at $27.66 per share. 5,006
08/19/2021 Reid S. McCarthy
Director
500   Acquisition at $37.61 per share. 18,805
07/01/2021 Maria-Luisa Maccecchini
President and CEO; Director
1,000   Gift at $0 per share. 0
07/01/2021 Maria-Luisa Maccecchini
President and CEO; Director
1,000   Gift at $0 per share. 0
07/15/2020 Maria-Luisa Maccecchini
President and CEO; Director
10,000   Gift at $0 per share. 0
04/27/2020 Maria-Luisa Maccecchini
President and CEO; Director
10,000   Gift at $0 per share. 0
02/03/2020 Jeffrey B. McGroarty
Chief Financial Officer
164   Acquisition at $7.17 per share. 1,175
02/03/2020 Jeffrey B. McGroarty
Chief Financial Officer
19,336   Acquisition at $7.15 per share. 138,252
/news/latest/company/us/anvs

MarketWatch News on ANVS

  1. Annovis Bio stock price target cut to $70 from $150 at Maxim Group

    6:43 a.m. Oct. 8, 2021

    - Tomi Kilgore

  2. Analyst Raises Price Targets on 3 Smaller Alzheimer's Stocks

    10:50 a.m. July 7, 2021

    - Barron's Online

  3. Annovis Bio stock price target raised to $150 from $45 at Maxim Group

    7:30 a.m. July 7, 2021

    - Tomi Kilgore

  4. Annovis Bio stock price target raised to $45 from $12 at Maxim Group

    6:33 a.m. May 13, 2021

    - Tomi Kilgore

  5. Annovis Bio started at buy with $12 stock price target at Maxim Group

    6:57 a.m. June 18, 2020

    - Tomi Kilgore

/news/nonmarketwatch/company/us/anvs

Other News on ANVS

  1. Annovis (ANVS) Gains on FDA Authorization for AD Study

    11:57 a.m. Oct. 7, 2022

    - Zacks.com

  2. ANVS, ARQQ and ALLG among mid-day movers

    12:04 p.m. Sept. 12, 2022

    - Seeking Alpha

  3. 10-Q: ANNOVIS BIO, INC.

    10:46 a.m. Aug. 8, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  4. GOGL, PRTY and ANVS are among pre market gainers

    7:33 a.m. July 7, 2022

    - Seeking Alpha

  5. Anavex's Blarcamesine: Why It May Treat Alzheimer's Disease

    6:28 p.m. June 2, 2022

    - Seeking Alpha

  6. Loading more headlines...

At a Glance

Annovis Bio, Inc.

1055 Westlakes Drive

Suite 300

Berwyn, Pennsylvania 19312

Phone

1 6107273913

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

N/A

Net Income

$-14.49M

Employees

3.00

/news/pressrelease/company/us/anvs

Press Releases on ANVS

  1. Annovis Bio to Present at the 2022 ThinkEquity Investor Conference

    6:31 a.m. Oct. 20, 2022

    - PR Newswire - PRF

  2. Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders

    6:30 a.m. Sept. 8, 2022

    - PR Newswire - PRF

  3. Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer

    3:00 p.m. Aug. 29, 2022

    - PR Newswire - PRF

  4. Loading more headlines...
Link to MarketWatch's Slice.